(Alliance News) - London's FTSE 100 ended flat as tariff worries kept enthusiasm to a minimum on Friday, while the pound edged slightly lower after a dramatic week in Westminster. Read More
(Alliance News) - London's blue chip index remained lower at midday on Friday, as investors weigh China's decision to slap levies on major European brandy exporters, and as US trading partners brace for letters on their respective tariff rates. Read More
(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone. Read More
(Alliance News) - London's FTSE 100 is called lower on Friday, as investors await a potential US announcement on tariff rates for trading partners and the UK prime minister reflects on his "good relationship" with US President Donald Trump. Read More
(Alliance News) - The FTSE 100 and sterling rallied, while the bond market calmed on Thursday as Keir Starmer supported his chancellor, reassuring markets that a change at the Treasury wasn't on the cards. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The long-serving chief executive of AstraZeneca, Britain's most valuable public company, would like to move the stock market listing to the US, the Times reported on Tuesday. Read More
(Alliance News) - London's FTSE 100 ended an up and down trading session firmly in the green on Tuesday despite ongoing US trade policy uncertainty and mixed economic data. Read More
(Alliance News) - London's FTSE 100 is called to open higher, while the dollar and Brent fell as US President Donald Trump announced a ceasefire in the Iran-Israel conflict. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said Datroway has secured US Food & Drug Administration approval for use in adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer. Read More
(Alliance News) - London's FTSE 100 faded into the close on Friday, ending lower, as weak retail sales data and falls in heavyweight oil and drug stocks offset hopes for progress in the Israel-Iran conflict. Read More
(Alliance News) - The FTSE 100 ended higher on Monday, just shy of a record closing high, on reports Iran is willing to resume nuclear talks with the US. Read More
(Alliance News) - AstraZeneca PLC on Friday reported an AI-focused collaboration with Shijiazhuang City, China-based CSPC Pharmaceutical Group Ltd, boosting its existing presence in the country. Read More
(Alliance News) - AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. Read More
(Alliance News) - Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on phase III trial data presented at a major oncology conference. Read More
(Alliance News) - The FTSE 100 was called slightly lower on Monday, ahead of manufacturing PMI data from the UK and other regions, and following US President Donald Trump's claim that the US will double steel and aluminium import tariffs. Read More
(Alliance News) - AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage gastric cancer, compared to chemotherapy alone. Read More
(Alliance News) - The FTSE 100 outperformed in a mixed day for European equities, after the US Court of Appeals temporarily reinstated Donald Trump's tariffs. Read More
(Alliance News) - Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence algorithms. Read More
(Alliance News) - Angle PLC on Wednesday said its annual loss narrowed in 2024 as revenue rose and operating costs fell, though the company warned that market uncertainty and funding cuts were weighing on revenue so far this year. Read More